ArriVent BioPharma Reports Third Quarter 2026 Financial Results
ArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ArriVent BioPharma Reports Third Quarter 2026 Financial Results · Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLC · Presented encouraging Phase 1 data for ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies at ESMO · Dosed
How this was made
The 30-second read
Why it matters
Near-term trading focus is likely on how investors interpret FURVENT’s failure to meet the primary PFS endpoint versus the reported antitumor activity (ORR) and the company’s stated plan to review the full dataset. Separately, the disclosed cash and investment balance informs financing risk and runway into mid-2028.
Market read
The filing combines a material clinical setback (primary endpoint miss) with supportive efficacy signals and a quantified cash runway, creating a decision point for biotech risk pricing and expectations for upcoming 2027 trial updates.
What to watch
Cash runway to mid-2028 may reduce dilution fears, and the planned Q1 2027 firmonertinib update could reframe the probability of regulatory pathways if the dataset review supports accelerated-approval arguments.
ArriVent reports Q3 2026 net loss of $(40,313) thousand after FURVENT Phase 3 missed its primary PFS endpoint; cash and investments of $393.2 million expected to fund operations to mid-2028
The filing reports no meaningful product revenue, a net loss in both periods, and a Phase 3 FURVENT readout that did not meet its primary endpoint of progression-free survival by BICR. Early ADC data and the ALPACCA enrollment update are positives, but the filing does not provide figures that offset the pivotal miss in the period.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Collaboration revenue, three months ended September 30, 2026GAAP | $5M | – | – |
| Research and development expenses, three months ended September 30, 2026GAAP | $38.90M | – | – |
| General and administrative expenses, three months ended September 30, 2026GAAP | $9.48M | – | – |
| Total operating expenses, three months ended September 30, 2026GAAP | $48.38M | – | – |
| Operating loss, three months ended September 30, 2026GAAP | −$43.38M | – | – |
| Interest and investment income, three months ended September 30, 2026GAAP | $3.06M | – | – |
| Net loss, three months ended September 30, 2026GAAP | −$40.31M | – | – |
| Unrealized gain (loss) on marketable securities, three months ended September 30, 2026GAAP | −$199K | – | – |
| Total comprehensive loss, three months ended September 30, 2026GAAP | −$40.51M | – | – |
| Net loss per share, basic and diluted, three months ended September 30, 2026GAAP | $(0.81) | – | – |
| Collaboration revenue, nine months ended September 30, 2026GAAP | $5M | – | – |
| Research and development expenses, nine months ended September 30, 2026GAAP | $118.9M | – | – |
| General and administrative expenses, nine months ended September 30, 2026GAAP | $28.32M | – | – |
| Total operating expenses, nine months ended September 30, 2026GAAP | $147.2M | – | – |
| Operating loss, nine months ended September 30, 2026GAAP | −$142.2M | – | – |
| Interest and investment income, nine months ended September 30, 2026GAAP | $8.65M | – | – |
| Net loss, nine months ended September 30, 2026GAAP | −$133.5M | – | – |
| Unrealized gain (loss) on marketable securities, nine months ended September 30, 2026GAAP | −$480K | – | – |
| Total comprehensive loss, nine months ended September 30, 2026GAAP | −$134.0M | – | – |
| Net loss per share, basic and diluted, nine months ended September 30, 2026GAAP | $(2.82) | – | – |
| Net cash used in operations, nine months ended September 30, 2026other | $122.2M | – | – |
| Cash and investments as of September 30, 2026other | $393.2M | – | – |
Capital returns
- No share repurchases or dividends are reported in the filing.
What drove it
- Collaboration revenue of $5,000 thousand was reported for both the three and nine months ended September 30, 2026, against no collaboration revenue printed for the 2025 periods.
- Research and development expenses rose to $38,897 thousand for the quarter from $32,167 thousand a year earlier, while nine-month R&D fell to $118,853 thousand from $121,176 thousand.
- General and administrative expenses were $9,479 thousand for the quarter and $28,324 thousand for nine months, against $6,149 thousand and $17,535 thousand in the prior-year periods. The filing does not explain the increase.
- Interest and investment income was $3,063 thousand for the quarter, down from $3,338 thousand, and $8,651 thousand for nine months, up from $7,947 thousand.
- The filing states that Phase 3 FURVENT did not meet its primary endpoint of PFS by BICR. At 240 mg, median PFS was 11.0 months versus 9.5 months with chemotherapy (HR 0.75; p=0.0654), and confirmed ORR by BICR was 60% versus 33%.
- The company reports preliminary Phase 1 ARR-217 data in evaluable colorectal cancer patients at 6 mg/kg: objective response rate of 44.8% and disease control rate of 93.1%.
Concerns
- FURVENT did not meet its primary PFS endpoint by BICR. The reported HR of 0.75 has p=0.0654.
- The company is reviewing differences between BICR and investigator-assessed PFS in the chemotherapy arm, and the firmonertinib update is planned for the first quarter of 2027.
- The company reported a net loss of $(40,313) thousand for the quarter and $(133,526) thousand for nine months, with no product revenue reported in the filing.
- General and administrative expenses for nine months rose to $28,324 thousand from $17,535 thousand, and the filing gives no explanation.
- Dr. Stuart Lutzker, co-founder and President of Research and Development, announced his retirement. The filing describes him as the architect of the ADC pipeline.
What to watch
- Firmonertinib update on the FURVENT review, planned for the first quarter of 2027, including the BICR versus investigator-assessed PFS analysis.
- Enrollment progress in the global Phase 3 ALPACCA study, which includes an interim analysis of objective response rate for a potential accelerated approval pathway.
- Phase 1b dose optimization data for ARR-217 in late-line colorectal cancer, expected in the first half of 2027, and combination data with bevacizumab and chemotherapy, expected in the second half of 2027.
- Early Phase 1a/1b data for ARR-002, the first patient of which was dosed in the period, in ovarian and endometrial cancers.
- Cash runway, which the company states extends to mid-2028, and the pace of cash use against the $122.2 million nine-month operating outflow.
Balance sheet and cash flow
- Cash and cash equivalents as of September 30, 2026: $113,583 thousand (December 31, 2025: $45,540 thousand).
- Short-term investments as of September 30, 2026: $279,640 thousand (December 31, 2025: $267,281 thousand).
- Total assets as of September 30, 2026: $417,089 thousand (December 31, 2025: $333,169 thousand).
- Total liabilities as of September 30, 2026: $23,613 thousand (December 31, 2025: $25,945 thousand).
- Total stockholders' equity as of September 30, 2026: $393,476 thousand (December 31, 2025: $307,224 thousand).
- Accumulated deficit as of September 30, 2026: $(538,167) thousand (December 31, 2025: $(404,641) thousand).
- Additional paid-in capital as of September 30, 2026: $932,104 thousand (December 31, 2025: $711,847 thousand).
- Company states cash and investments of $393.2 million as of September 30, 2026 are expected to fund operations to mid-2028.
- Net cash used in operations was $122.2 million for the nine months ended September 30, 2026, compared with $129.9 million for the nine months ended September 30, 2025.
Analysis
ArriVent's Q3 2026 release is dominated by the FURVENT Phase 3 result. The company reports that the study did not meet its primary endpoint of progression-free survival by blinded independent central review. Firmonertinib at 240 mg showed median PFS of 11.0 months against 9.5 months with chemotherapy (HR 0.75; p=0.0654) and a confirmed BICR objective response rate of 60% against 33%. The company says it is reviewing the full dataset, including differences between BICR and investigator-assessed PFS in the chemotherapy arm, before deciding on next steps. The firmonertinib update is scheduled for the first quarter of 2027.
The income statement shows almost no commercial activity. Collaboration revenue was $5,000 thousand in both the three and nine months ended September 30, 2026, and no collaboration revenue is printed for the 2025 periods. Operating expenses are the main line item. Research and development was $38,897 thousand in the quarter, up from $32,167 thousand a year earlier, while nine-month R&D was $118,853 thousand, down from $121,176 thousand. General and administrative expense rose sharply to $28,324 thousand for nine months from $17,535 thousand. The filing does not explain that increase. The quarterly net loss was $(40,313) thousand against $(34,978) thousand, and the nine-month net loss was $(133,526) thousand against $(130,764) thousand. Net loss per share was $(0.81) for the quarter and $(2.82) for nine months, against $(0.83) and $(3.54) in the prior-year periods. The nine-month per-share figure is lower than the prior year despite a larger loss, and the weighted-average share count, which the filing prints, rose substantially. The filing does not provide the quarter-over-quarter comparison, so the sequential trend cannot be read from it.
On the balance sheet, cash and cash equivalents were $113,583 thousand and short-term investments were $279,640 thousand at September 30, 2026, which the company summarizes as cash and investments of $393.2 million. Against December 31, 2025, total assets rose to $417,089 thousand from $333,169 thousand. Additional paid-in capital rose to $932,104 thousand from $711,847 thousand, which is consistent with equity issuance during 2026, although the filing does not describe any financing transaction. Net cash used in operations was $122.2 million for nine months, compared with $129.9 million a year earlier. The company states the balance will fund operations to mid-2028.
The pipeline news is mixed in scope. Preliminary Phase 1 data for ARR-217 at ESMO showed a 44.8% objective response rate and a 93.1% disease control rate in evaluable colorectal patients treated at 6 mg/kg, with the company describing the toxicities as predominantly low-grade. The first patient was dosed in the U.S. Phase 1a/1b study of ARR-002, and enrollment continues in the ALPACCA Phase 3. The company also named Dr. Priti Patel as Chief Medical Officer and announced the retirement of co-founder Dr. Stuart Lutzker, who the release says was the architect of the ADC pipeline. The filing gives no guidance, so the results cannot be compared with prior expectations. The principal figures to monitor are the FURVENT review outcome, the ALPACCA enrollment pace, and the cash burn against the stated runway.
Management, verbatim
While FURVENT did not meet its primary endpoint, firmonertinib demonstrated clear antitumor activity, with an efficacy and safety profile consistent with prior studies.
Bing Yao, Ph.D., Chief Executive Officer
Dr. Lutzker has been the driving force behind our R&D vision.
Bing Yao, Ph.D., Chief Executive Officer
Not in the filing
stated, not guessed- Prior-quarter (Q2 2026) figures for all income statement lines, so quarter-over-quarter changes cannot be given.
- Year-over-year percentage changes for all metrics, which the filing does not print.
- Full statements of cash flows, including the financing activities behind the rise in additional paid-in capital.
- Balance sheet comparison as of September 30, 2025, and cash and investments as of December 31, 2025 printed as a single figure.
- Company financial guidance or outlook for 2026 or later periods.
- Consensus estimates and any share price reaction, which the filing does not contain.
- Explanation of the change in general and administrative expenses.
- Detail on the Chief Medical Officer compensation arrangements referenced under Item 5.02, which are not printed in the document provided.
- Revenue breakdown by segment or product, because the company reports no segments.
- Quarter-level collaboration revenue for the three months ended September 30, 2025 is printed as a dash, so no numeric prior-year figure exists for that line.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This SEC 8-K furnishes Q3 2026 financial results and operational updates for ArriVent’s lead EGFR inhibitor firmonertinib and its ADC pipeline (ARR-217, ARR-002), plus leadership changes.
Ticker impact
ArriVent BioPharma filed an 8-K with Q3 2026 results plus clinical updates, including ALPACCA enrollment status and FURVENT failing its PFS endpoint.
Likely choppy trading as investors weigh the missed primary endpoint against supportive efficacy signals and the extended funding runway.
The filing is company-specific and includes concrete trial outcomes (PFS miss, ORR strength), plus a quantified cash balance expected to fund operations to mid-2028, which can offset near-term financing risk.
Market effects
Adds incremental sentiment to EGFR-mutant NSCLC and ADC development risk-reward, but does not change sector-wide guidance.
Primarily impacts US biotech sentiment for clinical-stage oncology developers.
Includes ESMO-presented ADC data and China approvals for the lead drug, but the filing is US-listed and mainly affects AVBP positioning.
Counterpoint
The primary endpoint miss in FURVENT could dominate valuation despite ORR strength, especially if investors discount investigator versus BICR differences.
Key entities
- companyArriVent BioPharma, Inc.
Nasdaq-listed clinical-stage biotech; reported Q3 2026 results and pipeline/trial updates via SEC 8-K.
- drug_programfirmonertinib
Oral EGFR inhibitor in Phase 3 ALPACCA and Phase 3 FURVENT; FURVENT missed primary PFS by BICR but showed ORR and safety consistency.
- clinical_trialALPACCA
Global pivotal Phase 3 study in first-line EGFR PACC-mutant NSCLC; enrollment remains on track and interim ORR analysis is planned for potential accelerated pathway.
- clinical_trialFURVENT
Phase 3 study whose primary endpoint (PFS by BICR) was not met; company is reviewing dataset differences to determine next steps.
- drug_programARR-217
CDH17-targeted ADC in Phase 1; ESMO presentation reported ORR and disease control rates in colorectal cancer.
